Skip to main content

Genmab Value Stock - Dividend - Research Selection

Genmab A/S

ISIN: DK0010272202, WKN: 565131

Market price date: 21.01.2022
Market price: 2.235,00 DKK


Genmab A/S Fundamental data and company key figures of the share

Annual reports in DKK
Key figures 10-09-2021
Cash flow
Net operating cash flow 6.433.000.000
Capital Expenditures -307.000.000
Free cash flow 6.126.000.128
Balance sheet
Total Equity 19.121.000.000
Liabilities & Shareholders equity 21.143.000.000
Income statement
Net income 4.758.000.000
Eps (diluted) 72,737
Diluted shares outstanding 65.413.600
Net sales/revenue 10.111.000.000

Fundamental ratios calculated on: 21-01-2022

Ratios
Key figures 21-01-2022
Cash flow
P/C 22,73
   
P/FC 23,87
Balance sheet
ROI22,50
ROE90,44
Income statement
P/E30,73
Div. Yield0,00%
P/B7,65
P/S14,46


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolGMAB.CO
Market Capitalization20.708.423.680,00 USD
CountryDenmark
IndicesSTOXX EUROPE 600,MSCI World Index
SectorsPharmaceuticals
Raw Data SourceIFRS in Millionen DKK
Stock Split
Internetwww.genmab.com


Description of the company

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.genmab.com


NEWS